TERRA VEJRASKA: Open Payments
NPI 1992052104 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$806 in 40 payments from 9 companies in 2025. Trend: 2023 $750 · 2024 $896 · 2025 $806
Food & beverage: $707Education: $99
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 5 | $236 |
| MAYNE PHARMA COMMERCIAL LLC | 17 | $203 |
| Sumitomo Pharma America, Inc. | 4 | $91 |
| ABBVIE INC. | 4 | $86 |
| Biogen, Inc. | 4 | $85 |
| Organon LLC | 2 | $35 |
| Exeltis, USA Inc. | 2 | $31 |
| Hologic Sales and Service, LLC | 1 | $23 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $15 |
Products named: Veozah, ZURZUVAE, MYFEMBREE, LILETTA, NEXPLANON, SLYND, GEMTESA, QULIPTA.
Industry payments across NE — which companies pay providers there.
